Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention

Kruglikov IL.

Prospective Study on Face & Skin, Systemic / IV, published in J Cosmet Dermatol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Cosmet Dermatol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41316800
PMCID
PMC12663710
DOI
10.1111/jocd.70584
Citations
4

Abstract (original English)

Background The emergence of a distinct facial appearance characterized by pronounced hollowing of the cheeks, temples, chin, and periorbital region has become a noteworthy side effect of treatment with glucagon-like peptide 1 receptor agonists (GLP-1RAs). This phenomenon presents a growing concern in both dermatology and aesthetic medicine. The reduction of facial adipose tissue in patients receiving GLP-1RAs often exceeds the overall weight and fat loss typically associated with these agents, suggesting that the effect cannot be fully attributed to systemic metabolic changes alone. Instead, it raises the possibility of localized, tissue-specific mechanisms of GLP-1RA action within facial fat depots. Aim In this article, we explore the underlying pathophysiology of this selective facial fat loss and discuss potential strategies for mitigating or reversing the aesthetic impact of GLP-1RAs. Conclusion Since the local effects of GLP-1RAs are realized through internalization of GLP-1 receptors (canonical pathway) or IGF-1R (non-canonical pathway), the suppression of mechanisms responsible for this internalization can be used to prevent the development of partial lipodystrophy after the application of GLP-1RAs. One encouraging possibility for such a preventive intervention can be the local modulation of CAV1 in the facial adipose tissue during the GLP-1RAs treatment course.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
FaceAdipose TissueHumansLipodystrophyReceptor, IGF Type 1Hypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research